Latest news with #AstraZeneca
Yahoo
5 hours ago
- Business
- Yahoo
Is AstraZeneca (AZN) a Reliable Dividend Stock for Long-Term Investors?
AstraZeneca PLC (NASDAQ:AZN) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases. AstraZeneca PLC (NASDAQ:AZN) has a strong lineup of drugs in development, which should help it navigate upcoming patent expirations. By the end of the first quarter, it had secured around 13 drug approvals or label updates. Among its most promising experimental treatments are two potential weight management drugs, AZD5004 and AZD6234. Overall, the company is working on nearly 200 programs in its research pipeline. In the first quarter of 2025, AstraZeneca PLC (NASDAQ:AZN) reported revenue of $13.6 billion, which showed a 7% growth from the same period last year. Total revenue has grown across all key regions, with core operating profit rising by 12%. The company is also planning to ramp up its investment in manufacturing and research in the U.S., building on its major R&D centers in Gaithersburg, Maryland, and Cambridge, Massachusetts. Overall, it is steadily moving closer to its goal of reaching $80 billion in total revenue by 2030. AstraZeneca PLC (NASDAQ:AZN) currently pays an interim dividend of $1.03 per share and has a dividend yield of 2.25%, as of July 17. It is one of the best dividend stocks in the pharma sector as the company has been paying regular dividends to shareholders for the past 32 years. While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.
CTV News
10 hours ago
- Health
- CTV News
Regina resident receives scholarship from AstraZeneca, one of 10 recipients across Canada
A scholarship worth $10,000 has been given to a non-for-profit leader that lives in Regina. 'Break The Divide' will be given $10,000 to bring climate awareness education towards youth in Regina. It's a moment to reflect and see how far they've come. Their first initiatives started in Surrey, B.C. as a high initiative, working with students in the Northwest Territories. The founder and executive director, Abhay Singh Sachal, who is studying at the University of Regina, is now localizing upcoming programs in the city. 'To pair up young people with other activist people that have been taking action and living in a sustainable way, that's really what it's all about.' he said. The sum, given by AstraZeneca, a biopharmaceutical company, will be giving an eighteen-month fellowship to Break The Divide, who have the green light to start up their own leadership initiatives. Break The Divide Courtesy: Break The Divide Foundation Break The Divide hopes to help students and teachers provide more education and how to deal with climate emotions, while also figuring out how Regina and Canada can be more sustainable going forward. 'There are a lot of emotions about the state of the world and about climate change,' said Singh Sachal. 'Here in Saskatchewan, we see the effects. Now every summer and throughout the year, we've seen extreme drought. We're seeing forest fires that we've never seen before. Sachal was the lone Saskatchewan representative to receive a scholarship from AstraZeneca for the 'Eureka Fellowship for Youth Changemakers in Canada'. Four scholarships were given to Ontario citizens, three in British Columbia, and two in Quebec. 'We've been hearing directly from young people about how they feel about the state of the environment in Regina and in Saskatchewan over the past year,' Singh Sachal said. 'What they've said is very clear, they want better urban density, they want walkable areas of the city, and they want improved transit. All of those are climate solutions that help everyone. Young people have also talked about ties with the fossil fuel industry, and the ways in which we continue to pollute and extract from the lands. A lot of Indigenous youth have talked about Indigenous ways of knowing and connecting with nature, being one with the land.' Since starting back in 2017, Break The Divide has expanded internationally in places such as Peru, South Africa and India.
Yahoo
a day ago
- Business
- Yahoo
Is AstraZeneca (AZN) a Reliable Dividend Stock for Long-Term Investors?
AstraZeneca PLC (NASDAQ:AZN) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases. AstraZeneca PLC (NASDAQ:AZN) has a strong lineup of drugs in development, which should help it navigate upcoming patent expirations. By the end of the first quarter, it had secured around 13 drug approvals or label updates. Among its most promising experimental treatments are two potential weight management drugs, AZD5004 and AZD6234. Overall, the company is working on nearly 200 programs in its research pipeline. In the first quarter of 2025, AstraZeneca PLC (NASDAQ:AZN) reported revenue of $13.6 billion, which showed a 7% growth from the same period last year. Total revenue has grown across all key regions, with core operating profit rising by 12%. The company is also planning to ramp up its investment in manufacturing and research in the U.S., building on its major R&D centers in Gaithersburg, Maryland, and Cambridge, Massachusetts. Overall, it is steadily moving closer to its goal of reaching $80 billion in total revenue by 2030. AstraZeneca PLC (NASDAQ:AZN) currently pays an interim dividend of $1.03 per share and has a dividend yield of 2.25%, as of July 17. It is one of the best dividend stocks in the pharma sector as the company has been paying regular dividends to shareholders for the past 32 years. While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Yahoo
2 days ago
- Business
- Yahoo
Factbox-Foreign firms' executives entangled in Chinese probes
BEIJING (Reuters) -U.S. bank Wells Fargo has suspended all travel to China after one of its employees was barred from leaving the country, extending a trend of foreign executives caught up in probes by authorities that has chilled business sentiment. Below are some other recent examples: - A Beijing court this week sentenced a Japanese employee of Astellas Pharma to 3-1/2 years in prison. The man had been detained since March 2023 on suspicion of spying and had been indicted about a year ago. - In March, Chinese authorities released employees of U.S. corporate due diligence firm Mintz Group detained in Beijing two years ago. Five of the firm's local staff were detained in a raid that turned out to be the beginning of a sweeping crackdown on consultancy and due diligence firms, including Bain & Company's office in Shanghai. A Singaporean executive at Mintz was also prevented from leaving China, sources told Reuters. China fined Mintz about $1.5 million in July 2024 for doing "unapproved statistical work". - Anglo-Swedish pharmaceutical firm AstraZeneca saw its China president Leon Wang detained and placed under investigation in 2024, with little information about what the probe was about. Wang, who grew up in China, was a high-profile executive often quoted in the Chinese business press. AstraZeneca's CEO said in February that the company was not permitted to speak with Wang, who has been placed under extended leave since December. Chinese media had reported that AstraZeneca was under probe since 2021, suspected of fabricating genetic testing results related to the firm's lung cancer drug Tagrisso and of insurance fraud. - A senior Nomura Holdings banker overseeing the Japanese firm's investment banking operations in China was ordered not to leave the mainland, sources told Reuters in late 2023. The exit ban was lifted the following year allowing Charles Wang Zhonghe, China investment banking chairman at Nomura, to return to Hong Kong, where he was previously based, according to the Financial Times. - Michael Chan, a senior executive at U.S. risk advisory firm Kroll, was barred from leaving the Chinese mainland, the Wall Street Journal reported in September 2023. The Hong Kong passport holder was assisting in an investigation dating back a few years, the newspaper reported, citing people familiar with the matter. Neither Kroll nor Chan was the target of the investigation, according to the newspaper. - A Singapore-based UBS wealth manager was prevented from leaving China in 2018. The executive was asked to remain in the country to meet with local authorities, Reuters reported at that time. The uncertainty surrounding the exit ban on the wealth manager had led the Swiss bank and several of its rivals to require their private banking staff to carefully consider trips to China.
Reuters
2 days ago
- Business
- Reuters
Foreign firms' executives entangled in Chinese probes
BEIJING, July 18 (Reuters) - U.S. bank Wells Fargo (WFC.N), opens new tab has suspended all travel to China after one of its employees was barred from leaving the country, extending a trend of foreign executives caught up in probes by authorities that has chilled business sentiment. Below are some other recent examples: - A Beijing court this week sentenced a Japanese employee of Astellas Pharma (4503.T), opens new tab to 3-1/2 years in prison. The man had been detained since March 2023 on suspicion of spying and had been indicted about a year ago. - In March, Chinese authorities released employees of U.S. corporate due diligence firm Mintz Group detained in Beijing two years ago. Five of the firm's local staff were detained in a raid that turned out to be the beginning of a sweeping crackdown on consultancy and due diligence firms, including Bain & Company's office in Shanghai. A Singaporean executive at Mintz was also prevented from leaving China, sources told Reuters. China fined Mintz about $1.5 million in July 2024 for doing "unapproved statistical work". - Anglo-Swedish pharmaceutical firm AstraZeneca (AZN.L), opens new tab saw its China president Leon Wang detained and placed under investigation in 2024, with little information about what the probe was about. Wang, who grew up in China, was a high-profile executive often quoted in the Chinese business press. AstraZeneca's CEO said in February that the company was not permitted to speak with Wang, who has been placed under extended leave since December. Chinese media had reported that AstraZeneca was under probe since 2021, suspected of fabricating genetic testing results related to the firm's lung cancer drug Tagrisso and of insurance fraud. - A senior Nomura Holdings (8604.T), opens new tab banker overseeing the Japanese firm's investment banking operations in China was ordered not to leave the mainland, sources told Reuters in late 2023. The exit ban was lifted the following year allowing Charles Wang Zhonghe, China investment banking chairman at Nomura, to return to Hong Kong, where he was previously based, according to the Financial Times. - Michael Chan, a senior executive at U.S. risk advisory firm Kroll, was barred from leaving the Chinese mainland, the Wall Street Journal reported in September 2023. The Hong Kong passport holder was assisting in an investigation dating back a few years, the newspaper reported, citing people familiar with the matter. Neither Kroll nor Chan was the target of the investigation, according to the newspaper. - A Singapore-based UBS (UBSG.S), opens new tab wealth manager was prevented from leaving China in 2018. The executive was asked to remain in the country to meet with local authorities, Reuters reported at that time. The uncertainty surrounding the exit ban on the wealth manager had led the Swiss bank and several of its rivals to require their private banking staff to carefully consider trips to China.
